Remission and Flare in Psoriatic Arthritis (ReFlaP) Study

• Research type

  Research Study

• Full title

  DEFINING CUT-OFF VALUES FOR WIDELY-USED COMPOSITE SCORES AND PATIENT-REPORTED OUTCOME MEASURES IN PSORIATIC ARTHRITIS, CORRESPONDING TO MINIMAL DISEASE ACTIVITY, PATIENT-REPORTED ACCEPTABLE STATE/REMISSION, AND FLARE ASSESSED BY THE PHYSICIAN AND THE PATIENT: A PROSPECTIVE 6-MONTH STUDY WITH A DOUBLE PERSPECTIVE

• IRAS ID

  229350

• Contact name

  Laura Coates

• Contact email

  laura.coates@ndorms.ox.ac.uk

• Sponsor organisation

  Groupe d’Etudes et de Recherche de l’appareil locomoteur

• Clinicaltrials.gov Identifier

  NCT03119805, Clinical Trials.gov

• Duration of Study in the UK

  1 years, 5 months, 30 days

• Research summary

  Psoriatic arthritis (PsA) is a chronic disease with a significant patient-perceived impact. Remission is the official objective of treatment. Flares are frequent but both concepts (remission and flare) are poorly defined. The objective of this study is to identify cutoffs for the most widely used composite scores and questionnaires corresponding to remission/low disease activity and flares, from both the patient and physician perspective.The study will recruit 500 patients in 15 countries.

• REC name

  South Central - Oxford A Research Ethics Committee

• REC reference

  17/SC/0436

• Date of REC Opinion

  15 Sep 2017

• REC opinion

  Favourable Opinion